Basking Biosciences
Basking Biosciences is a clinical-stage biopharmaceutical company dedicated to changing the way potentially life-threatening blood clots are treated. Its novel therapies are designed to significantly improve safety and efficacy, broadening access to many more patients. The company's lead candidate, BB-031, is the first rapid-onset, short-acting thrombolytic therapy with a reversal agent, currently in development for the treatment of acute ischemic stroke.
Leadership & Board
- Current Number of Employees
- 21
- Current LinkedIn Followers
- 1,997
Latest Estimated Valuation
- Estimated Valuation
- ―
- Total Amount Raised
- $28M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $28M
- Latest Funding Round
- Investment
- Post-Money Valuation
- ―
Company Momentum Positive
Basking Biosciences LinkedIn following is increasing, signaling rising market interest, while its workforce is growing, indicating business expansion.
Employee Trend
Basking Biosciences had 21 employees as of October 12, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Basking Biosciences had 1,997 followers as of October 12, 2026. The number of followers increased by 0 (0.00%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Oct 22, 2025 | Investment | $27.50M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Insight Partners | Investment |
| Longview Ventures | Investment |
| ARCH Venture Partners | Investment |
| Platanus | Investment |
| RTW | Investment |
| Solas BioVentures | Investment |
Similar Companies
A snapshot of private companies similar to Basking Biosciences, helping you discover and navigate related company profiles.
